stockrowBolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
Bolt Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, roughly unchanged from fiscal 2024.
- Revenue
- −99.7%
- EPS
- −2.47%
- Free cash flow
- +38.9%
- Total debt
- −14.3%
Quarter to June 2026, against a year earlier
Follow BOLT
Alert me
Bolt Biotherapeutics, Inc. (BOLT) Altman Z-score
Bolt Biotherapeutics, Inc.'s Altman Z-score for fiscal 2025 is −12.67, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −12.67 | (5.03) |
| FY2024 | −7.64 | (4.10) |
| FY2023 | −3.54 | (1.74) |
| FY2022 | −1.79 | (2.21) |
| FY2021 | 0.42 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.38 | — | 0.46 | |
| Retained earnings / total assets | (8.12) | — | −11.37 | |
| EBIT / total assets | (0.64) | — | −2.10 | |
| Market value of equity / total liabilities | 0.34 | — | 0.20 | |
| Sales / total assets | 0.14 | — | 0.14 | |
| Altman Z-score | Distress zone | −12.67 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −27.30 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | −6.7× |
| GUTS Fractyl Health, Inc. compare | −7.0× |
| LPCN Lipocine Inc. compare | −7.7× |
| DARE Dare Bioscience, Inc. compare | −8.9× |
| BOLT Bolt Biotherapeutics, Inc. | −12.7× |
| HIND Vyome Holdings, Inc. compare | −22.0× |
| CASIF CASI Pharmaceuticals Inc. compare | −47.1× |
| AEON AEON Biopharma, Inc. compare | — |
| PBM Psyence Biomedical Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets